Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Single Dose and Multiple Ascending Dose, Single Center Phase1 Study of Safety, Tolerability, Pharmacokinetics, and Electroencephalography of Intravenous GATE-202 in Healthy Volunteers

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single Dose and Multiple Ascending Dose, Single Center Phase1 Study of Safety, Tolerability, Pharmacokinetics, and Electroencephalography of Intravenous GATE-202 in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apimostinel (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Biomarker
  • Sponsors Gate Neurosciences; Syndeio Biosciences

Most Recent Events

  • 27 May 2025 According to Syndeio Biosciences media release, Gate Neurosciences name changed to Syndeio Biosciences.
  • 15 May 2024 According to Gate Neurosciences media release, data from this study will be presented at the 2024 annual meeting of the American Society of Clinical Psychopharmacology (ASCP),
  • 07 Nov 2023 Positive topline results assessing the qEEG biomarker and safety results from its Phase 1 multiple ascending dose study of apimostinel from this study, presented in a Gate Neurosciences media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top